Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarkers of Lupus Disease (BOLD)
NCT00987831Phase 2Completed
- Sponsor
- Oklahoma Medical Research Foundation
- Start
- May 2009
- Primary completion
- Dec 2012
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of methylprednisolone injection in systemic lupus erythematosus (SLE) (3 arms), sponsored by Oklahoma Medical Research Foundation. Primary endpoint: Time to Flare Comparing Patients With Moderate vs Severe Disease Activity at Baseline at 12 months. Started May 2009; status: completed.
02
Drugs
methylprednisolone injection
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT00987831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00987831.